Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Olson

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The Journal of Family Practice|April 15, 2020
Can diabetes be cured?Allan Olson
Journal of Clinical Gastroenterology|April 9, 2005
Unemployment and disability in patients with moderately to severely active Crohn's diseaseBrian G Feagan, Mohan Bala, Songkai Yan, et al.
Current Medical Research and Opinion|November 26, 2005
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's diseaseKarel Geboes, Paul Rutgeerts, Ghislain Opdenakker, et al.
Pharmacogenetics and Genomics|November 17, 2006
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I studyEdouard J Louis, Hervé E Watier, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2004
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's diseaseStephen B Hanauer, Carrie L Wagner, Mohan Bala, et al.
The Lancet. Gastroenterology & Hepatology|October 22, 2018
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 scoreVipul Jairath, Jenny Jeyarajah, Guangyong Zou, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
The American Journal of Gastroenterology|February 28, 2007
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsBrian G Feagan, Walter Reinisch, Paul Rutgeerts, et al.
Pharmacogenetics|October 3, 2002
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trialsSilvia Mascheretti, Jochen Hampe, Peter J P Croucher, et al.
Inflammatory Bowel Diseases|May 4, 2007
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisWalter Reinisch, William J Sandborn, Mohan Bala, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Family Practice|April 15, 2020
Can diabetes be cured?Allan Olson
Journal of Clinical Gastroenterology|April 9, 2005
Unemployment and disability in patients with moderately to severely active Crohn's diseaseBrian G Feagan, Mohan Bala, Songkai Yan, et al.
Current Medical Research and Opinion|November 26, 2005
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's diseaseKarel Geboes, Paul Rutgeerts, Ghislain Opdenakker, et al.
Pharmacogenetics and Genomics|November 17, 2006
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I studyEdouard J Louis, Hervé E Watier, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2004
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's diseaseStephen B Hanauer, Carrie L Wagner, Mohan Bala, et al.
The Lancet. Gastroenterology & Hepatology|October 22, 2018
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 scoreVipul Jairath, Jenny Jeyarajah, Guangyong Zou, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
The American Journal of Gastroenterology|February 28, 2007
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsBrian G Feagan, Walter Reinisch, Paul Rutgeerts, et al.
Pharmacogenetics|October 3, 2002
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trialsSilvia Mascheretti, Jochen Hampe, Peter J P Croucher, et al.
Inflammatory Bowel Diseases|May 4, 2007
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisWalter Reinisch, William J Sandborn, Mohan Bala, et al.
Pageof 3